Seller record · Telehealth service

Oak

By Peptide Alliance, Editorial publisherRecorded August 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: Orders are fulfilled through licensed US compounding pharmacies; none is named. 2 more criteria also fail; see the table below.

At a glance

OakTelehealth service

5/8criteria passed

Price: Programs from $119 a month
Sells: compounded semaglutide, tirzepatide, NAD+, and 3 more
FDA letters: None on file

Partner link. The site earns a commission on care started through it. Funding

Visit Oak See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth weight-loss service selling compounded semaglutide and tirzepatide. It discloses no United States business address, and it names no filling pharmacy.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Oak's website
S2	Prescription gating	PASS	Oak's weight loss page
S3	Pharmacy identification	FAIL	Oak's website
S4	Compounding disclosure	PASS	Oak's product page
S5	Analytical documentation	FAIL	Oak's product page
S6	Business address	FAIL	Oak's privacy policy
S7	Price disclosure	PASS	Oak's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date. A row that was re-checked later states its own date.

S1PASSThe site states every prescription is reviewed by a board-certified provider.Source: Oak's website.

S2PASSA qualification step and physician review precede any prescription.Source: Oak's weight loss page.

S3FAILOrders are fulfilled through licensed US compounding pharmacies; none is named.Source: Oak's website.

S4PASSStates plainly that compounded drugs are not FDA-approved as finished products.Source: Oak's product page.

S5FAILThe product page publishes four named tests marked as passed, for potency within plus or minus 10 percent, sterility, pH and endotoxicity, and names no laboratory, no lot and no reachable document.Source: Oak's product page · read September 2026.

S6FAILNo US street address anywhere on the site; the privacy policy is written for Canada.Source: Oak's privacy policy.

S7PASSPrices printed on public pages: programs from $119 monthly.Source: Oak's website.

S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, tirzepatide, NAD+, glutathione, sermorelin, tadalafil.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+Who sells glutathione

Partner link. The site earns a commission on care started through it. Funding.

Visit Oak

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.